Dosing & Uses
Multiple Myeloma
Pending FDA approval for relapsed or refractory multiple myeloma
Next:
Pharmacology
Mechanism of Action
Bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen, with potential antineoplastic activity
Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells, which results in cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte response against GPRC5D-expressing tumor cells
GPRC5D is overexpressed on certain tumors (eg, multiple myeloma), while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
